Status:

UNKNOWN

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Collaborating Sponsors:

Gilead Sciences

Conditions:

Hepatitis D

Hepatitis B

Eligibility:

All Genders

18+ years

Brief Summary

In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infec...

Eligibility Criteria

Inclusion

  • Positive HBV surface antigen (HBsAg)
  • Age 18 yeas and above

Exclusion

  • 1\. Severe cardiac, renal, respiratory, hematological, or psychiatric illness.

Key Trial Info

Start Date :

November 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2023

Estimated Enrollment :

5000 Patients enrolled

Trial Details

Trial ID

NCT05394623

Start Date

November 1 2022

End Date

July 1 2023

Last Update

November 2 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study) | DecenTrialz